Loading organizations...

§ Venture Capital · USA, Canada, Europe
Venture capital firm investing in technology companies across AI, life sciences, fintech, and enterprise software, from seed to growth stages.
GV is the venture capital investment arm of Alphabet Inc., providing seed, venture, and growth-stage funding to technology companies from its headquarters in Mountain View, California. Operating independently from Google's core business, the firm focuses on financial returns across sectors including artificial intelligence, life sciences, fintech, robotics, and enterprise software. With over $10 billion in assets under management and $8 billion in total funds raised, GV maintains an active portfolio of approximately 400 companies. Its notable investments include early backing for companies such as Uber, Slack, Nest, Flatiron Health, and more recently, AI-native applications like Harvey and Synthesia. The firm has invested in over 300 companies in total, with typical check sizes ranging from $500K to $50M+. GV was originally launched as Google Ventures in 2009, rebranding to its current name in 2015.
Key people at GV.
Key people at GV.
GV (formerly Google Ventures) is Alphabet Inc.’s independent venture capital arm with over $10 billion in assets under management, supporting founders at every stage—from seed to growth. Its mission is to back innovative entrepreneurs and help them build transformative companies by providing not only capital but also strategic guidance, operational support, and access to Google and Alphabet’s vast resources and expertise. GV invests across a broad range of sectors including technology, healthcare, life sciences, artificial intelligence, cybersecurity, transportation, and agriculture. It has backed over 400 active companies, including notable names like Uber, Nest, Slack, GitLab, and Stripe, playing a significant role in shaping the startup ecosystem by fostering innovation and scaling impactful technologies[1][2][3].
GV was founded in 2009 by Bill Maris with an initial $100 million capital commitment, aiming to create a venture fund that combined the reliability of a single limited partner (Alphabet) with the autonomy and technical expertise of a traditional VC. Initially branded as Google Ventures, it operated independently from Google’s core search and advertising business, rebranding to GV in 2015 to emphasize this independence. Over time, GV evolved from a broad seed investor to focusing more on mature companies and sectors like healthcare and biotech, launching or investing in companies such as Calico and Editas Medicine. Key partners have included Bill Maris (founder and first CEO) and more recently Michael McBride, who leads GV’s AI-native startup investments[1][3][4].
GV rides the wave of rapid technological innovation across AI, healthcare, and deep tech, sectors experiencing significant market expansion and transformation. Its timing is critical as AI-native startups and biotech innovations reshape industries globally. Market forces such as increasing demand for AI applications, healthcare advancements, and digital transformation favor GV’s investment focus. By bridging startup innovation with Alphabet’s resources, GV accelerates commercialization and adoption of breakthrough technologies, influencing the broader ecosystem by setting standards for venture support and fostering cross-sector innovation[1][3][7].
Looking ahead, GV is poised to deepen its leadership in AI and life sciences investing, capitalizing on trends like AI-native applications, photonic computing, and gene editing. Its influence will likely grow as it continues to back foundational technologies that enable new industries and business models. GV’s long-term horizon and operational support model position it to remain a key player in venture capital, driving innovation that shapes the future of technology and healthcare. The firm’s ability to leverage Alphabet’s ecosystem while maintaining independent investment judgment will be crucial in navigating evolving market dynamics and sustaining its impact on the startup landscape[7][1][3].
GV has more than 26 tracked investments across 24 companies. The latest tracked deal is $40.0M Other Equity in Mestag Therapeutics in March 2026.